Use of the malaria drugs chloroquine and hydroxychloroquine to prevent and treat Covid-19 has been a focus of intense public attention. President Trump has promoted the promise of hydroxychloroquine, despite the absence of gold-standard evidence from randomised clinical trials to prove its effectiveness, and recently said he was taking it himself in hopes of preventing coronavirus infection.
The scientists’ challenges to the Lancet paper come at a time of increasing debate about the risks of the rush to publish new medical findings about Covid-19. The paper, published May 22, included data on tens of thousands of patients hospitalised through April 14, meaning that the authors analysed the trove of data, wrote the paper and went through the journal’s peer review of its findings in just over five weeks, much faster than usual.